BGPT: Paper Review: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

Explore by Goal

Quick Explanation Copied

I-SPY 2's adaptive Bayesian design showed veliparib–carboplatin added to standard neoadjuvant chemotherapy produced a 51% (95% PI, 36–66) pathological complete response rate in triple-negative breast cancer versus 26% (95% PI, 9–43) with control, with 88% predicted phase 3 success, but with substantial hematologic toxicity (71% neutropenia). The later phase 3 BrighTNess trial found veliparib added no pCR benefit over carboplatin alone (53% vs 58%), confirming the I-SPY 2 signal largely reflected carboplatin.

Long Explanation

What the I-SPY 2 veliparib–carboplatin data show

Among patients with HER2-negative disease, the estimated pathological complete response (pCR) rate was 33% (95% PI, 23–43) with veliparib–carboplatin versus 22% (95% PI, 10–35) with control; the effect concentrated in the triple-negative (TNBC) signature at 51% (95% PI, 36–66) versus 26% (95% PI, 9–43), with 99% probability of superiority and an 88% Bayesian predictive probability of phase 3 success. In hormone-receptor-positive/HER2-negative tumors, veliparib–carboplatin showed no benefit (14% vs 19%; 28% superiority probability).

The trial was explicitly not powered to separate veliparib from carboplatin, and the authors themselves note that concurrent GeparSixto (53% vs 37% pCR, P=0.005) and CALGB 40603 (54% vs 41%, P=0.003) trials showed carboplatin alone improved TNBC pCR rates—making carboplatin the most probable driver of much of the I-SPY 2 signal. The subsequent 634-patient BrighTNess phase 3 trial confirmed this concern: veliparib–carboplatin–paclitaxel achieved 53% pCR versus 58% with carboplatin–paclitaxel—no added benefit from veliparib.

Consequences of the toxicity burden were concrete: 47% required carboplatin dose reductions, 32% paclitaxel reductions, and 18% discontinued paclitaxel early (mostly for toxicity), versus 2% early discontinuation in controls—yet pCR estimates still favored the experimental arm despite dose attenuation, a point in its favor.

Critical blind spots

BGPT inference: (1) The adaptive randomization enriched the veliparib arm for BRCA-mutated patients (17% vs 7%), and the paper states DNA-repair-deficiency results were collected but not reported—an unreported biomarker interaction that could explain part of the TNBC effect. (2) The reported Bayesian estimates "carry greater precision than a raw-data estimate," meaning the 95% PIs understate the uncertainty of only 72 vs 44 patients. (3) pCR is a validated surrogate for TNBC event-free survival, but long-term survival data were not mature at publication. (4) The manufacturer supplied veliparib but played no role in design or analysis—an appropriately disclosed arrangement, though AbbVie later ran and co-analyzed the confirmatory BrighTNess trial, which is the pattern of sponsor involvement worth scrutinizing. (5) Veliparib monotherapy failed in BRCA-mutated pancreatic cancer (0 confirmed responses, median OS 3.1 months), reinforcing that veliparib's contribution as a chemosensitizer—and not a PARP-inhibitor single-agent effect—was the operative question, one BrighTNess largely answered negatively.

The durable legacy of this paper is methodological: it was the first I-SPY 2 regimen to "graduate," demonstrating that adaptive Bayesian platform trials can rapidly identify biomarker-defined winners and direct small, focused phase 3 trials. What would change this assessment: maturing event-free survival data showing no TNBC benefit from veliparib–carboplatin, or a replicable biomarker (e.g., the organoid-derived PARPi7 model, AUC 0.912 for VC response in TNBC) identifying the subset genuinely sensitive to veliparib rather than carboplatin.

Feedback:

Updated: November 01, 2026